No­var­tis to seek ac­cel­er­at­ed ap­proval for oral com­ple­ment in­hibitor in rare kid­ney dis­ease

Last year
R&D
FDA+

Sy­ros lays off 35% of work­ers, re­places CEO and los­es CSO af­ter axed pacts

Last year
People
R&D

Q3 snap­shot: The IPO mar­ket shows fresh signs of im­prove­ment, but the biotech crunch con­tin­ues to bite

Last year
Bioregnum

Ex­clu­sive: Prov­i­dence just launched a start­up for one of hos­pi­tals’ biggest prob­lems — main­tain­ing pa­tient ...

Last year
Health Tech

FDA re­jects Eli Lil­ly’s eczema drug due to third-par­ty man­u­fac­tur­ing is­sues 

Last year
FDA+
Manufacturing

Ex­clu­sive: Di­men­sion leads $40M round for lab au­toma­tion com­pa­ny Au­toma­ta Tech­nolo­gies

Last year
Financing

In­fin­i­ty Phar­ma­ceu­ti­cals files for bank­rupt­cy af­ter lay­offs, scrapped merg­er with MEI Phar­ma

Last year
Pharma

Ex­clu­sive: 'Faster is­n't bet­ter' — Atom­wise moves from part­ner­ships to pipeline with TYK2 drug

Last year
R&D
AI

Cor­rect­ed: Syn­dax stops PhI/II leukemia study ear­ly af­ter menin in­hibitor shows ef­fi­ca­cy in chal­leng­ing mu­ta­tion

Last year
R&D

Katal­in Karikó, Drew Weiss­man win No­bel Prize for mR­NA dis­cov­er­ies

Last year
People

Ex-Warp Speed vac­cine leader nabs NextGen funds for Mod­eX Ther­a­peu­tics’ Covid-19 an­ti­bod­ies

Last year
Deals
Coronavirus

Tak­ing pulse on pri­vate biotech fund­ing; Q&A with Iso­mor­phic Labs CEO; Re­search in­sti­tu­tions re­thinks deal­mak­ing; and ...

Last year
Weekly

Lex­eo Ther­a­peu­tics and Abi­vax seek Nas­daq list­ings in shrink­ing pre-Thanks­giv­ing win­dow for biotech IPOs

Last year
Financing

Sen. Bill Cas­sidy calls on hos­pi­tals to pro­vide more in­for­ma­tion on how they use 340B funds

Last year
Pharma

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

Last year
FDA+

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

Last year
FDA+

GSK’s Vi­iV Health­care set to launch sec­ond sea­son of LGBTQ+ Lat­inx ‘te­len­ov­ela-style’ pod­cast with celeb voic­es

Last year
Marketing

In­de­pen­dent phar­ma and health­care ad agency The Bloc takes its busi­ness around the world

Last year
Marketing

Madri­gal rais­es $500M for NASH drug launch, dis­clos­es cy­ber­at­tack

Last year
Financing

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Last year
R&D
In Focus

How End­points News will cov­er the fu­ture of the health­care in­dus­try

Last year
Health Tech

Mer­ck KGaA's ex­pand­ed AI deal; As­cle­tis has new bio­mark­er da­ta for its PD-L1; De­ka clos­es $20M round

Last year
News Briefing

MEI Phar­ma push­es back on ac­tivist in­vestors af­ter failed merg­er with In­fin­i­ty

Last year
Pharma

With its ex-No­var­tis can­cer drug near the fin­ish line, Ad­lai Nortye rais­es $97.5M in Nas­daq de­but

Last year
Financing
First page Previous page 271272273274275276277 Next page Last page
A service from the Financial Times